TCTR20230126001已完成2 期
Feasibility Study of the Kardion Cory P4 MCS System
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 90 Years（—）
- 性别
- All
入选标准
- •Subjects must meet all of the following criteria:
- •Subject age at least 18 and less than than or equal to 90 years of age
- •The patient requires a non-emergent PCI and has an LV ejection fraction of < 50% requiring hemodynamic support during the procedure and has been deemed to be suboptimal for cardiac surgery AND at high risk due to any of the following:
- •Unprotected Left Main Stenosis
- •Last remaining vessel
- •Significant three vessel disease (or two-vessel disease in a dominant left system)
- •The patient is willing and able to comply with the protocol-specified treatment and follow-up evaluations
- •The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)
排除标准
- •Subjects must not meet any of the following criteria:
- •Emergency Procedure
- •Any prior coronary revascularization or revascularization attempt within 30 days prior to procedure
- •STEMI within 7 days prior to procedure - defined as new ST elevation at the J point in at least 2 contiguous leads of greater than or equal to 2 mm (0.2 mV) in men or greater than or equal to 1.5 mm (0.15 mV) in women in leads V2-V3 and/or of greater than or equal to 1 mm (0.1 mV) in other contiguous chest leads or the limb leads
- •Cardiac arrest within 7 days prior to procedure requiring CPR or defibrillation
- •Subject indicated to require cardiac support with an MCS System post procedure
- •Subjects with sustained ventricular tachycardia or repetitive / prolonged non-sustained ventricular tachycardia or complex ventricular ectopy
- •Left ventricular thrombus
- •Significant right heart failure
- •Combined cardiorespiratory failure
- •Presence of an atrial or ventricular septal defect (including post-infarct VSD)
- •Hypertrophic obstructive cardiomyopathy (HOCM)
- •Cardiogenic shock (Cardiac index < 1.8 l/min/meters squared) or pre-procedure use of inotropic or pressor therapy within 72 hours of the planned index procedure
- •Moderate or severe aortic valve insufficiency, stenosis or aortic valve replacement (mechanical prosthesis)
- •Aortic vascular disease (i.e. aortic aneurysm, dissection, extreme tortuosity or calcification creating additional risk to the placement of an MCS device)
- •CVA/TIA within 90 days prior to procedure
- •Known or suspected coagulopathy or abnormal coagulation parameters (defined as platelet count less than or equal to 100,000 or spontaneous INR greater than or equal to 1.5 or known fibrinogen less than or equal to 1.5 g/l)
- •Known hemoglobin diseases, such as sickle cell anemia or thalassemia
- •Patient has been diagnosed with or is recently suffering from infectious disease
- •Chronic renal dysfunction (eGFR < 30 mL/min/1.73 meters squared) and patients requiring renal replacement therapy with dialysis
- •History of liver dysfunction with elevation of liver enzymes and bilirubin 3 times the upper limit of normal (ULN)
- •Known or suspected severe pulmonary disease (e.g. forced expiratory volume (FEV)1 < 1.0 l/s) or requiring supplemental oxygen
- •Allergy, sensitivity or tolerance to anesthesia, heparin, aspirin, adenosine, diphosphate (ADP) receptor blockers, or contrast media, including known heparin-induced thrombocytopenia (HIT)
- •Any non-cardiac condition with life expectancy < 3 years (e.g. cirrhosis, oxygen or oral steroid dependent COPD, cancer, etc.)
- •Subject is presently or recently intubated for the current admission (NOTE: recently intubated patients must be extubated for > 24 hours with full neurologic recovery)
- •Decompensated heart failure within the last 3 months that required hospitalization (admitting diagnosis)
- •Morbid obesity (BMI greater than or equal to 40 kg/meters squared)
- •Patients with an organ transplant
- •Patients with implanted left ventricular assist device
- •Cardiac tamponade
- •Left ventricular rupture
- •Tuberculosis, hepatitis, HIV-infection or other severe viral diseases
- •Suspected or known pregnancy or lactating women
- •Active COVID-19 infection
- •Anatomic situations that limit delivery of the MCS Device, like severe peripheral arterial occlusive disease (PAOD)
- •Other diseases or therapies that restrict the use of an MCS Device
- •Subject has other medical,
研究者
相似试验
招募中
Unknown
Feasibility study on the use of the CV-4 Cranio Sacral Technique to increase attention in children with Attention Deficit. A randomized controlled trialAttention deficit disorder with and without hyperactivity (ADD/ ADHD) in childhoodDRKS00030428Therapiezentrum Dr. Thomas Riedhart12
Enrolling By Invitation
不适用
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum DisorderNeuromyelitis Optica Spectrum DisorderNCT06374264MedRhythms, Inc.30
尚未招募
不适用
Computerized training of children with ADHD between 6-11 yearsCTRI/2022/11/046953AIIMS Delhi
撤回
不适用
A Study of the CardiAQ-Edwards ™ Transcatheter Mitral Valve (TMV) System for patients requiring mitral valve replacementCardiovascular - Other cardiovascular diseasesSurgery - Surgical techniquesMitral RegurgitationACTRN12618000103268Edwards Lifesciences, LLT15
招募中
2 期
The feasibility and safety study of the functional recovery therapy using a HAL for the central motor dysfunction.Stroke, brain/spinal cord injury, brain/spinal cord tumor, neuromuscular diseaseJPRN-jRCTs032180149Yamazaki Masashi285